Higher Oxidative Stress Linked to Metabolic Syndrome

Share this content:
Higher Oxidative Stress Linked to Metabolic Syndrome
Higher Oxidative Stress Linked to Metabolic Syndrome

THURSDAY, Dec. 22, 2016 (HealthDay News) -- Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome (MetS) and its components, according to a study published online Dec. 19 in Diabetes.

Yamilee Hurtado-Roca, M.D., from the Centro Nacional de Investigaciones Cardiovasculares Carlos III in Madrid, and colleagues examined the correlation between oxidative stress and MetS using data from 3,987 subjects without diabetes in the Progression of Early Subclinical Atherosclerosis study.

The researchers found that after adjustment for age, sex, smoking, LDL cholesterol, body mass index, waist circumference, and homeostatic model assessment of insulin resistance (HOMA-IR), the odds ratios for MetS for the second, third, and fourth quartiles of ox-LDL versus the first quartile were 0.84 (95 percent confidence interval, 0.52 to 1.36), 1.47 (95 percent confidence interval, 0.95 to 2.32), and 2.57 (95 percent confidence interval, 1.66 to 4.04) (P < 0.001 for trend). For all MetS components except glucose concentration, results showed the same trend. Overall, 13.9 percent of the association between waist circumference and triglycerides was mediated by ox-LDL, as was 1 to 3 percent of the association between waist circumference and high-density lipoprotein cholesterol, blood pressure, and insulin resistance. The correlation between ox-LDL and MetS components was not mediated by HOMA-IR.

"Ox-LDL may reflect core mechanisms through which MetS components develop and progress in parallel with insulin resistance and could be a clinically relevant predictor of MetS development," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »